Glucagon-like peptide-1 receptor agonists and the risk of atrial fibrillation in adults with diabetes: a real-world study.

ABSTRACT:

Background

Glucagon-like peptide-1 receptor agonists (GLP-1RA) have cardiovascular benefits in type 2 diabetes, but none of the cardiovascular trials studied atrial fibrillation/atrial flutter (AF) as a primary endpoint. Data from post-marketing surveillance studies remains sparse.

Objective

To examine the real-world risk of AF comparing GLP-1RA with other non-insulin glucose-lowering agents.

Design

Cohort study using de-identified electronic health record data from the Optum Labs Data Warehouse.

Participants

Adult patients with diabetes who were newly prescribed add-on non-insulin glucose-lowering agents and were on metformin between 2005-2020.

Exposures

New users of GLP-1RA were separately compared with new users of dipeptidyl peptidase-4 inhibitors (D

SUBMITTER: Xu Y 

PROVIDER: S-EPMC11116290 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature